Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
Scotiabank analyst George Farmer maintains a Sector Outperform rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $34 to $19.
April 18, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Scotiabank maintains a Sector Outperform rating on Sage Therapeutics but lowers the price target from $34 to $19.
The reduction in price target by Scotiabank, despite maintaining a positive Sector Outperform rating, could lead to short-term negative sentiment among investors. This adjustment reflects a significant decrease in the expected stock price, potentially affecting investor confidence and stock performance in the near term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100